Demonstration of the blood-stage plasmodium falciparum controlled human malaria infection model to assess efficacy of the p. falciparum apical membrane antigen 1 Vaccine, FMP2.1/AS01

Journal of Infectious Diseases

Volumn 213, Issue 11, 2016, Pages 1743-1751

  Payne, Ruth O ^a,b   Milne, Kathryn H ^a   Elias, Sean C ^a   Edwards, Nick J ^a   Douglas, Alexander D ^a   Brown, Rebecca E ^a   Silk, Sarah E ^a   Biswas, Sumi ^a   Miura, Kazutoyo ^g   Roberts, Rachel ^b   Rampling, Thomas W ^a,b   Venkatraman, Navin ^a,b   Hodgson, Susanne H ^a,b   Labbé, Geneviève M ^a   Halstead, Fenella D ^a   Poulton, Ian D ^b   Nugent, Fay L ^a   De Graaf, Hans ^d,e   Sukhtankar, Priya ^d,e   Williams, Nicola C ^c   Ockenhouse, Christian F ^h,i   Kathcart, April K ^h   Qabar, Aziz N ^h   Waters, Norman C ^h   Soisson, Lorraine A ^j   Birkett, Ashley J ⁱ   Cooke, Graham S ^f   Faust, Saul N ^d,e   Woods, Colleen ⁱ   Ivinson, Karen ⁱ   McCarthy, James S ^k   Diggs, Carter L ^j   Vekemans, Johan ^l   Long, Carole A ^g   Hill, Adrian V S ^a   Lawrie, Alison M ^b   Dutta, Sheetij ^h   Draper, Simon J ^a   more..

^a UK   (France)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ PATH Malaria Vaccine Initiative   (United States)

^j UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^k QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^l GSK   (Belgium)

more..

Author keywords

AMA1; blood stage; CHMI; Malaria; Vaccine

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; IMMUNOGLOBULIN G; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MALARIA VACCINE; MEMBRANE PROTEIN; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; MALARIA FALCIPARUM; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; UNITED KINGDOM; VACCINATION; BIOLOGICAL MODEL; CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHROCYTE; IMMUNOLOGY; LIFE CYCLE STAGE; MALARIA, FALCIPARUM; MIDDLE AGED; PARASITOLOGY; PHYSIOLOGY; VACCINE IMMUNOGENICITY; YOUNG ADULT;

ADULT; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSPOT ASSAY; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; LIFE CYCLE STAGES; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; YOUNG ADULT;

EID: 84978689385     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw039     Document Type: Article

References (44)

1. Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. Lancet 2013; 382:1700-1.
2. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31-45.
3. Halbroth BR, Draper SJ. Recent developments in malaria vaccinology. Adv Parasitol 2015; 88:1-49.
4. Goodman AL, Draper SJ. Blood-stage malaria vaccines-recent progress and future challenges. Ann Trop Med Parasitol 2010; 104:189-211.
5. Sheehy SH, Douglas AD, Draper SJ. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother 2013; 9:1831-40.
6. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011; 11:57-64.
7. Roestenberg M, O'Hara GA, Duncan CJ, et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 2012; 7: e38434.
8. Spring MD, Cummings JF, Ockenhouse CF, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 2009; 4:e5254.
9. Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 2012; 20:2355-68.
10. McCarthy JS, Sekuloski S, Griffin PM, et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One 2011; 6:e21914.
11. Sheehy SH, Spencer AJ, Douglas AD, et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One 2013; 8:e65960.
12. Engwerda CR, Minigo G, Amante FH, McCarthy JS. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol 2012; 28:515-21.
13. Duncan CJ, Draper SJ. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg 2012; 86:561-5.
14. Duncan CJ, Sheehy SH, Ewer KJ, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-Adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 2011; 6:e22271.
15. Stanisic DI, Liu XQ, De SL, et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J 2015; 14:143.
16. Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, et al. NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis 2013; 207:656-60.
17. Spring M, Murphy J, Nielsen R, et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013; 31:4975-83.
18. Hodgson SH, Juma E, Salim A, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 2014; 5:686.
19. Shekalaghe S, Rutaihwa M, Billingsley PF, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014; 91:471-80.
20. McCarthy JS, Griffin PM, Sekuloski S, et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis 2013; 208:1688-94.
21. Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, Hill AV. Bloodstage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008; 78:878-83.
22. Lawrence G, Cheng QQ, Reed C, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000; 18:1925-31.
23. Douglas AD, Andrews L, Draper SJ, et al. Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis 2011; 203:1337-40.
24. Douglas AD, Edwards NJ, Duncan CJ, et al. Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. J Infect Dis 2013; 208:340-5.
25. Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 2008; 24:74-84.
26. Dutta S, Lalitha PV, Ware LA, et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 2002; 70:3101-10.
27. Thera MA, Doumbo OK, Coulibaly D, et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One 2008; 3:e1465.
28. Thera MA, Doumbo OK, Coulibaly D, et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS One 2010; 5:e9041.
29. Polhemus ME, Magill AJ, Cummings JF, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 2007; 25:4203-12.
30. Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011; 365:1004-13.
31. Ewer KJ, O'Hara GA, Duncan CJ, et al. Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013; 4:2836.
32. Hodgson SH, Ewer KJ, Bliss CM, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 2015; 211:1076-86.
33. Hodgson SH, Choudhary P, Elias SC, et al. Combining viral vectored and proteinin-Adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther 2014; 22:2142-54.
34. Miura K, Zhou H, Diouf A, et al. Anti-Apical-membrane-Antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 2009; 16:963-8.
35. Biswas S, Choudhary P, Elias SC, et al. Assessment of humoral immune responses to blood-Stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One 2014; 9:e107903.
36. Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-Based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 2015; 17:130-9.
37. Chuang I, Sedegah M, Cicatelli S, et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-Mediated immunity. PLoS One 2013; 8:e55571.
38. Sedegah M, Hollingdale MR, Farooq F, et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS One 2014; 9:e106241.
39. Ouattara A, Takala-Harrison S, Thera MA, et al. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 2013; 207:511-9.
40. Laurens MB, Thera MA, Coulibaly D, et al. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One 2013; 8:e79323.
41. Dutta S, Sullivan JS, Grady KK, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009; 4:e8138.
42. Boyle MJ, Reiling L, Feng G, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 2015; 42:580-90.
43. Llewellyn D, Miura K, Fay MP, et al. Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria. Sci Rep 2015; 5:14081.
44. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015; 522:487-91.